ALX Oncology's Evorpacept Gets Orphan Drug Tag For Gastric Cancer

by Vandana Singh, Benzinga Editor
January 28, 2022 8:02 AM | 1 min read |

The FDA has granted Orphan Drug Designation to ALX Oncology Holdings Inc's ALXO evorpacept for gastric cancer and gastroesophageal junction cancer.

  • In ASPEN-01, patients with >2L HER2 positive gastric (n=18) treated with evorpacept combined with trastuzumab plus ramucirumab and paclitaxel demonstrated an initial objective response rate of 72.2% with a median duration of response of 14.8 months and a median overall survival of 17.1 months. 
  • Related content: Benzinga's Full FDA Calendar.
  • These results compare favorably with the clinical experience with both ramucirumab plus paclitaxel and trastuzumab-deruxtecan in similar populations. 
  • Also See: ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation.
  • The Company is enrolling ASPEN-06 Phase 2/3 study of evorpacept for advanced HER2 positive gastric cancer.
  • Price Action: ALXO shares closed at $14.36 on Thursday
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: BiotechNewsHealth CareSmall CapFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!